Zensar does have a patchy execution track record and the turnaround thesis will not be without certain quarters of misses (as seen recently in H1 FY23). That said, valuations at <1x FY24 EV/Sales and 24% of market cap in cash adequately facto that a healthy cash buffer of US$ 179m (24% of M.Cap) also provides support to its valuation.